Compounds > N-(4-hydroxyphenyl)-8-quinolinesulfonamide
Page last updated: 2024-12-09

N-(4-hydroxyphenyl)-8-quinolinesulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID894115
CHEMBL ID1530310
CHEBI ID107375
SCHEMBL ID808364

Synonyms (16)

Synonym
OPREA1_515863
MLS000115777 ,
smr000092793
n-(4-hydroxyphenyl)-8-quinolinesulfonamide
AQ-390/41698577
CHEBI:107375
AKOS001681256
n-(4-hydroxyphenyl)quinoline-8-sulfonamide
STK946815
HMS2258B08
SCHEMBL808364
bdbm60397
cid_894115
CHEMBL1530310
Q27185682
PD096054
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency19.95260.631035.7641100.0000AID504339
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency56.23410.531815.435837.6858AID504845
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.50120.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency9.92370.036619.637650.1187AID2100
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
Guanine nucleotide-binding protein GHomo sapiens (human)Potency1.25891.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
large T antigenBetapolyomavirus macacaeIC50 (µMol)7.36000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
oxidative phosphorylationCytochrome b-c1 complex subunit 7Homo sapiens (human)
mitochondrial electron transport, ubiquinol to cytochrome cCytochrome b-c1 complex subunit 7Homo sapiens (human)
aerobic respirationCytochrome b-c1 complex subunit 7Homo sapiens (human)
cellular respirationCytochrome b-c1 complex subunit 7Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingCytochrome b-c1 complex subunit 7Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
mitochondrial inner membraneCytochrome b-c1 complex subunit 7Homo sapiens (human)
mitochondrial respirasomeCytochrome b-c1 complex subunit 7Homo sapiens (human)
mitochondrial respiratory chain complex IIICytochrome b-c1 complex subunit 7Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1630569Induction of cartilage repair in collagenase2-induced osteoarthritis rat model assessed as recovery of cartilage thickness at 10 uM on day 7 and 21 by safranin O/fast green staining-based optical microscopic analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1630570Induction of differentiation in human ASC after 11 days by alcian blue staining based analysis relative to control2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1630576Upregulation of aggrecan expression in collagenase2-induced osteoarthritis rat model injected with 10 uM compound-treated human ASC on day 7 and 21 by immunohistochemistry2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1165236Modulation of UQCRB in human HepG2 cells assessed as inhibition of HIF-1alpha for 4 hrs under 1%O2 by Western blot analysis2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Development of a novel class of mitochondrial ubiquinol-cytochrome c reductase binding protein (UQCRB) modulators as promising antiangiogenic leads.
AID1630571Chondrogenic activity in human ASC assessed as increase in aggrecan expression incubated for 11 days by sandwich ELISA relative to control2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1630574Induction of cartilage repair in collagenase2-induced osteoarthritis rat model assessed as recovery of cartilage thickness injected with 10 uM compound-treated human ASC on day 7 and 21 by safranin O/fast green staining-based optical microscopic analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1630568Chondrogenic activity in human ASC assessed as increase in aggrecan expression at 10 uM incubated for 11 days by sandwich ELISA relative to control2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1630575Induction of cartilage repair in collagenase2-induced osteoarthritis rat model assessed as increase in proteoglycan content injected with 10 uM compound-treated human ASC + on day 7 and 21 by safranin O/fast green staining-based optical microscopic analys2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1630573Chondrogenic activity in human ASC assessed as increase in aggrecan expression at 10 uM incubated for 11 days in presence of MEK inhibitor U0126 by sandwich ELISA relative to control2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1630567Chondrogenic activity in human ASC assessed as increase in aggrecan expression at 1 uM incubated for 11 days by sandwich ELISA relative to control2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1630572Upregulation of ERK phosphorylation in human ASC at 0.1 to 1 uM by Western blot analysis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
AID1630577Upregulation of aggrecan expression in collagenase2-induced osteoarthritis rat model injected with 10 uM compound on day 7 and 21 by immunohistochemistry2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Potential therapeutic application of small molecule with sulfonamide for chondrogenic differentiation and articular cartilage repair.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.29 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		2.110retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510